#Pinnacle Medicines

3 stories

Pinnacle Medicines is one of several peptide-focused operators covered on this site, appearing in coverage of peptide-summit events, state-of-the-peptides reporting, and the broader policy landscape around 503A compounding.

Stories here cover product launches, investor updates, and the company's positioning in the peptide-policy fight. For broader policy, see #peptide-policy and #compounding.

Industry April 28, 2026 · View digest

Pinnacle Medicines Featured at Boston Summit: $89M Series B Backs Oral Peptides With Injectable Biologic-Level Efficacy

OrbiMed-incubated Pinnacle Medicines is featured at the Boston peptide summit highlighting its oversubscribed $89M Series B financing (closed March 26) for advancing oral peptide therapeutics designed to match the efficacy of injectable biologics. Lead programs target asthma, COPD, immunology, and inflammation — distinct from the GLP-1 obesity focus dominating peptide headlines. The platform combines proprietary peptide stabilization with oral-bioavailability engineering, positioning Pinnacle as one of the most differentiated non-GLP-1 oral peptide developers in the current pipeline.

Industry April 6, 2026 · View digest

Pinnacle Medicines Raises $89M for Oral Peptides Matching Injectable Biologics

OrbiMed-incubated startup revealed $89M in funding to develop oral peptide drugs with biologic-level efficacy. Lead program targets asthma and is on track for clinical trials.

Industry March 27, 2026 · View digest

Pinnacle Medicines Closes $89M Series B for AI-Driven Oral Peptide Pipeline

Pinnacle closed an oversubscribed $89M Series B (total $134M) to advance AI-driven oral peptide therapeutics into clinical trials, focusing on immunology and cardiometabolic diseases.